Document:

Exhibit 10.3

                              DATED 15TH MARCH 2010

                     (1) CANCER RESEARCH TECHNOLOGY LIMITED

                                       AND

                           (2) GENESIS BIOPHARMA, INC.

                           PATENT AND KNOW HOW LICENCE

                                       1
<PAGE>
THIS AGREEMENT IS MADE THE 15TH DAY OF MARCH 2010

BETWEEN:

(1)  CANCER RESEARCH  TECHNOLOGY  LIMITED,  a company  registered in England and
     Wales under  number  1626049  with  registered  office at  Sardinia  House,
     Sardinia Street, London WC2A 3NL, England ("CRT"); and

(2)  GENESIS BIOPHARMA, INC. (FORMERLY KNOWN AS FREIGHT MANAGEMENT CORPORATION),
     a company  incorporated  in the State of Nevada,  United  States of America
     whose  principal  place of business is at Suite 200, 8275 Eastern Ave., Las
     Vegas, Nevada, 89123 ("GENESIS BIOPHARMA").

RECITALS

(A)  CRT is an oncology focused technology transfer and development company.

(B)  CRT is wholly  owned by Cancer  Research  UK, a  company  registered  under
     number 4325234 and registered  charity number  1089464.  Cancer Research UK
     was formed as a result of the merger on 4 February  2002 of two  charities:
     the Cancer Research Campaign ("CRC") and Imperial Cancer Research Fund.

(C)  CRC  funded  research  concerning  the  [********]in  the  laboratories  of
     [****************]at     the     [*******************************]     (the
     "UNIVERSITY").  Pursuant to a Research  Collaboration  and Option Agreement
     dated 27th July 2000 made  between  CRT  (under  its former  name of Cancer
     Research Campaign Technology  Limited),  Viragen (Scotland) Limited and the
     University,  as amended by the Novation  Agreement dated 7th September 2001
     (the  "COLLABORATION  AGREEMENT"),  the research led to a novel therapeutic
     use of  [**********]antibodies  (the "INVENTION") and CRT is the registered
     proprietor of the application(s) for patent(s) described in Schedule 2 (the
     "SCHEDULED PATENTS") in respect of the Invention.  Under a letter agreement
     dated 11th November 2003 between  Viragen,  Inc.  ("VIRAGEN")  and CRT (the
     "LETTER  AGREEMENT"),  CRT granted a limited  licence to Viragen to certain
     intellectual  property  in  respect  of the  Invention.  The  Collaboration
     Agreement and Letter  Agreement  expired and Viragen (the parent company of
     Viragen  (Scotland)  Limited),  entered  into a patent and know how licence
     agreement  dated 27 April 2005 (the "2005 LICENCE") under which CRT granted
     Viragen an  exclusive  licence to the  Licensed  Intellectual  Property (as
     defined by the 2005 Licence,  the "2005 LICENSED  INTELLECTUAL  PROPERTY").
     During the term of the Letter  Agreement and 2005 Licence,  Viragen (either
     itself or through its wholly owned subsidiary Viragen  (Scotland)  Limited)
     generated certain Viragen Intellectual Property (defined in Clause 1).

(D)  [*******************************]   the  2005  Licence  was  terminated  in
     accordance  with its terms by CRT. In the interests of ensuring the further
     development of the  Invention,  CRT waived its rights to call for Viragen's
     rights  in the  Viragen  Intellectual  Property  (as  defined  in the  2005
     Licence) and the clinical  data  generated by Viragen  relating to the 2005
     Licensed  Intellectual  Property  to be  assigned to CRT. At the request of
     Viragen's  liquidators,   CRT  negotiated  and  concluded  a  licence  (the
     "PERCIPIO LICENCE" as defined below) [*******************************] with
     Percipio  Biotherapeutics,  Inc.  ("PERCIPIO")  to  ensure  the  commercial

                                       2
<PAGE>
     exploitation  of the Invention and  [*************]  antibody  programme to
     develop  Products (as defined in Clause 1). During the term of the Percipio
     Licence, Percipio generated certain PERCIPIO INTELLECTUAL PROPERTY (defined
     in Clause 1).

(E)  [*******************************] (i) the Viragen Intellectual Property was
     assigned to Hamilton  Atlantic,  a company  organized in the Cayman Islands
     ("HAMILTON"),  pursuant  to an  Assignation  executed  by Hamilton on 6 May
     2008; (ii) Hamilton entered into that certain License Agreement ("AGREEMENT
     I") effective as of August 20, 2008,  by and between  Hamilton and Percipio
     (formerly   known  as  Sunburst   Acquisitions   III,   Inc.,   a  Colorado
     corporation),   and  that  certain  License   Agreement   ("AGREEMENT  II,"
     collectively with Agreement I the "SUNBURST LICENSE AGREEMENTS")  effective
     as of August 21, 2008, by and between  Hamilton and  Percipio,  pursuant to
     which  Hamilton  agreed to license to  Percipio  the  Viragen  Intellectual
     Property;  and (iii) CRT and Hamilton  entered into that certain  Agreement
     effective as of October 21, 2008,  between CRT and Hamilton (the  "HAMILTON
     SIDE  AGREEMENT"),  pursuant  to which  Hamilton  agreed  to  grant  CRT an
     exclusive worldwide right and licence to the Viragen Intellectual  Property
     in the event that the Percipio Licence and Agreement II are terminated.

(F)  It is proposed that concurrent with this Agreement  Hamilton will terminate
     the Sunburst Licence  Agreements by agreement with Percipio and will assign
     the Viragen Intellectual Property to Genesis Biopharma pursuant to an asset
     purchase agreement (the "ASSET PURCHASE AGREEMENT").

(G)  It is proposed that concurrent with this Agreement CRT, Hamilton, Percipio,
     and  Genesis   Biopharma   will  enter  into  an  agreement  (the  "LICENCE
     TERMINATION AND WAIVER AGREEMENT")

(H)  Percipio has assigned all rights in the Percipio  Intellectual  Property to
     Genesis  Biopharma  as referred to in the  Licence  Termination  and Waiver
     Agreement.

NOW IT IS HEREBY AGREED AS FOLLOWS:

1. DEFINITIONS AND INTERPRETATION

1.1  In this  Agreement  and in the  Schedules to this  Agreement  the following
     words and phrases shall have the following meanings:

"Affiliate"                          means,   with  respect  to  a  Party,   any
                                     company, corporation,  partnership or other
                                     entity,   which   directly  or   indirectly
                                     Controls,  or is controlled by, or is under
                                     the   common   control   with  such   Party
                                     including  as  a   subsidiary,   parent  or
                                     holding company of such Party; and the term
                                     "Control"  means the ownership of more than
                                     fifty per cent  (50%) of the  issued  share
                                     capital  or the  legal  power to  direct or
                                     cause   the   direction   of  the   general
                                     management  and  policies  of the  relevant
                                     Party.

                                       3
<PAGE>
"Agreement"                          means this  document  entitled  "Patent and
                                     Know   How   Licence"   and   any  and  all
                                     schedules,  appendices and other addenda to
                                     it as may be varied or otherwise altered or
                                     amended  from  time to  time in  accordance
                                     with the provisions of Clause 13.3.

"Business                            Day"  means a day  other  than a  Saturday,
                                     Sunday,  bank or other  public  holiday  in
                                     England.

"Commencement Date"                  means the date first above written.

"Competent Authority"                means   any  local  or   national   agency,
                                     authority,    department,     inspectorate,
                                     minister,  ministry  official  or public or
                                     statutory  person  (whether  autonomous  or
                                     not) of any  government  or of any  country
                                     having  jurisdiction over this Agreement or
                                     of  any  of  the   Parties   or  over   the
                                     development   or   marketing  of  medicinal
                                     products including, but not limited to, the
                                     European Commission,  the European Court of
                                     Justice    and   the    Food    and    Drug
                                     Administration  of  the  United  States  of
                                     America.

"Confidential Information"           means  any and  all  information  which  is
                                     identified  and  treated by the  disclosing
                                     Party as secret and  confidential or which,
                                     by   reason   of  its   character   or  the
                                     circumstances  or manner of its disclosure,
                                     is evidently  secret and  confidential  and
                                     which  the  disclosing  Party  from time to
                                     time  discloses  to  the  recipient  Party,
                                     whether  orally,  in  writing,  in  digital
                                     form, in the form of machine  readable code
                                     or any other physical  medium which relates
                                     to  the  disclosing   Party,  its  business
                                     activities and  including,  but not limited
                                     to Know How, financial  information (except
                                     that   published   in  audited   accounts),
                                     business    strategies    or    intentions,
                                     marketing plans or  information,  formulae,
                                     inventions    or   product   or    services
                                     development.

"Development Plan"                   means the programme for the  development of
                                     Products to be  undertaken  by or on behalf
                                     of Genesis  Biopharma as more  particularly
                                     set out in Schedule 1 and as may be amended
                                     from  time  to  time  by  agreement  of the
                                     Parties in writing.

"European Economic Area"             means those  countries  that are members of
                                     the European  Economic Area as  constituted
                                     at the Commencement Date.

"Field"                              means  the field of use of  [********]  for
                                     the   immunotherapeutic   treatment  and/or
                                     diagnosis of diseases.

"Financing Event"                    means the receipt by Genesis  Biopharma  of
                                     at  least   [****************]   in  total,
                                     whether    in   a   single    tranche    or
                                     cumulatively, in cash.

                                       4
<PAGE>
"Genesis Biopharma Intellectual
Property"                            means  any Know  How,  Material  or  Patent
                                     Rights directly  related to the development
                                     of antibodies  directed  against [*****] or
                                     the Products,  whether as an improvement to
                                     the Licensed  Intellectual  Property and/or
                                     Viragen   Intellectual    Property   and/or
                                     Percipio     Intellectual    Property    or
                                     otherwise, discovered, invented, developed,
                                     or  manufactured  as a result  of  research
                                     undertaken by Genesis  Biopharma  itself or
                                     its Affiliates or Sub-licensees or research
                                     funded by Genesis  Biopharma but undertaken
                                     by a Third Party and undertaken pursuant to
                                     the licence in this Agreement.

"Force Majeure"                      means in relation to either Party any event
                                     or   circumstance   which  is  beyond   the
                                     reasonable  control  of that  Party,  which
                                     that Party could not reasonably be expected
                                     to  have   taken   into   account   at  the
                                     Commencement  Date and which  results in or
                                     causes the failure of that Party to perform
                                     any or all of its  obligations  under  this
                                     Agreement   including   an  act   of   God,
                                     lightning,  fire, storm, flood, earthquake,
                                     accumulation  of snow or ice, lack of water
                                     arising  from   weather  or   environmental
                                     problems,    strike,   lockout   or   other
                                     industrial disturbance, war, terrorist act,
                                     blockade,  revolution,  riot  insurrection,
                                     civil  commotion,   public   demonstration,
                                     sabotage, act of vandalism, prevention from
                                     or   hindrance  in  obtaining  in  any  way
                                     materials,   energy   or  other   supplies,
                                     explosion,  fault  or  failure  of plant or
                                     machinery,  governmental restraint,  act of
                                     legislature and directive or requirement of
                                     a Competent  Authority  governing any Party
                                     provided  that  lack of funds  shall not be
                                     interpreted   as   a   cause   beyond   the
                                     reasonable control of that Party.

"Indication"                         means a recognized disease or condition,  a
                                     significant  manifestation  of a disease or
                                     condition,  or symptoms  associated  with a
                                     disease  or  condition  or  a  risk  for  a
                                     disease or condition.  Notwithstanding  the
                                     foregoing, "Indication" as used in Clause 4
                                     shall  mean a specific  disease  indication
                                     differentiated  by tumor  types (as opposed
                                     to different  labels  within the same tumor
                                     type).

"In Vivo Efficacy Work"              means the work so  described as detailed in
                                     Part 1 of Stage 1 of the Development Plan.

"Initial Financing"                  means the receipt by Genesis  Biopharma  of
                                     the   sum   of    [***********************]
                                     pursuant to  commitments  made on or before
                                     the Commencement Date.

"Know How"                           means technical and other information which
                                     is  not  in the  public  domain  including,
                                     ideas, concepts,  inventions,  discoveries,

                                       5
<PAGE>
                                     data, formulae, specifications, information
                                     relating to Materials  (including  Licensed
                                     Materials),  procedures for experiments and
                                     tests and  results of  experimentation  and
                                     testing,    results   of    research    and
                                     development  including  laboratory  records
                                     and  data   analyses   which   is   secret,
                                     substantial and identifiable.

"Licensed Intellectual Property"     means the  Licensed  Know How, the Licensed
                                     Materials and the Licensed Patents.

"Licensed Know How"                  means  any  and  all  Know  How  set out in
                                     Schedule 3 to this Agreement.

"Licensed Materials"                 means (i) the [***********] antibody called
                                     [******]    and    (ii)    the    hybridoma
                                     [*****************************]   owned  by
                                     CRT.

"Licensed Patents"                   means   (i)   Patent   Application   Number
                                     [***************]    (and    all    foreign
                                     equivalents  thereof);  (ii)  any  and  all
                                     other   patent   application(s),   patents,
                                     divisionals,  continuations,  continuations
                                     in part and improvements arising therefrom;
                                     and (iii) any and all other  Patent  Rights
                                     obtained  in   pursuance   of  or  deriving
                                     priority  from the Patent  Rights listed in
                                     items (i) and (ii) hereof. A list of Patent
                                     Rights as of the  Commencement  Date is set
                                     forth in Schedule 2.

"Major Market"                       means  each  of  the  following  groups  of
                                     countries:

                                     (i)   [***************]

                                     (ii)  [***************]

                                     (iii) [***************]

"Marketing Plan"                     has the meaning set forth in Clause 3.5.

"Material"                           means any chemical or biological  substance
                                     directly related to the Licensed Materials,
                                     including any:

                                     (i)    organic   or   inorganic    chemical
                                            element or compound;

                                     (ii)   nucleotide  or  nucleotide  sequence
                                            including DNA and RNA sequences;

                                     (iii)  gene;

                                     (iv)   vector   or   construct    including
                                            plasmids, phages, or viruses;

                                       6
<PAGE>
                                     (v)    host  organism  including  bacteria,
                                            fungi,    algae,     protozoa    and
                                            hybridomas;

                                     (vi)   eukaryotic or prokaryotic  cell line
                                            or   expression    system   or   any
                                            development  strain  or  product  of
                                            that cell line or expression system;

                                     (vii)  protein including any peptide, amino
                                            acid sequence,  enzyme,  antibody or
                                            protein     conferring     targeting
                                            properties  and  any  fragment  of a
                                            protein,    peptide,    enzyme,   or
                                            antibody;

                                     (viii) drug or pro-drug;

                                     (ix)   other genetic or biological material
                                            or micro-organism; or

                                     (x)    assay or reagent.

"Net Sales"                          means [****************]
                                     [****************************************].

"Orphan Indication"                  means  an  Indication  which is rare in the
                                     general  population  in the  Territory,  as
                                     defined   by  the   controlling   Competent
                                     Authority  in the country of  interest,  as
                                     such definition may be amended from time to
                                     time.

"Parties"                            means CRT and Genesis Biopharma and "Party"
                                     shall be construed as any of them.

"Patent Rights"                      means  any  patent  applications,  patents,
                                     author certificates, inventor certificates,
                                     utility  certificates,  utility  models and
                                     all  foreign   counterparts   of  them  and
                                     includes    all    divisions,     renewals,
                                     continuations,       continuations-in-part,
                                     extensions,    reissues,     substitutions,
                                     provisional     applications,     continued
                                     prosecution   applications,   requests  for
                                     continued  examinations,   re-examinations,
                                     confirmations, registrations, revalidations
                                     and additions of or to them, as well as any
                                     supplementary  protection  certificate,  or
                                     like form of protection.

"Percipio Intellectual Property"     means  any Know  How,  Material  or  Patent
                                     Rights directly  related to the development
                                     of antibodies  directed  against  [******],
                                     whether as an  improvement  to the Licensed
                                     Intellectual    Property   or    otherwise,
                                     discovered,    invented,    developed,   or
                                     manufactured   as  a  result  of   research
                                     undertaken   by  Percipio   itself  or  its
                                     Affiliates  or  Sub-licensees  or  research
                                     funded  by  Percipio  but  undertaken  by a

                                       7
<PAGE>
                                     Third Party and whether undertaken pursuant
                                     to the Percipio  Licence or pursuant to the
                                     Sunburst  Licence  Agreement,  assigned  to
                                     Genesis Biopharma as referred to in Recital
                                     (G).

"Percipio Licence"                   means the Patent and Know How Licence dated
                                     21 October  2008 made  between  (1) CRT and
                                     (2) Percipio.

"Pivotal Registration Study"         means a clinical  study designed to provide
                                     the efficacy  data required to enable a new
                                     drug     application    or    other    like
                                     documentation  to be  filed  in the  United
                                     States of America or any Major Market.

"Product"                            means any item, thing or process that falls
                                     within  the scope of a  Licensed  Patent or
                                     that  uses  Licensed  Know  How,  or  which
                                     contains or was  developed  using  Licensed
                                     Materials,   or  any  Viragen  Intellectual
                                     Property or Percipio Intellectual Property.

"Quarter"                            means  any  period  of  three   consecutive
                                     calendar months commencing on 1 January,  1
                                     April, 1 July, or 1 October in any year.

"Revenue Share"                      [*****************************************]

"SPC"                                means a right based on the Licensed Patents
                                     or any of them pursuant to which the holder
                                     of the right is entitled  to exclude  Third
                                     Parties  from using,  making,  having made,
                                     selling, advertising or otherwise disposing
                                     or  offering to dispose  of,  importing  or
                                     keeping  the  product  to which  the  right
                                     relates,  such as Supplementary  Protection
                                     Certificates  in  Europe,  and any  similar
                                     right anywhere in the world.

"Sub-licence"                        means  a   sub-licence   of  the   Licensed
                                     Intellectual  Property  granted  by Genesis
                                     Biopharma  to  its  Affiliate  or  a  Third
                                     Party.

[*****************]                  [*****************************************]

"Sub-licensee"                       means   any   Third    Party   or
                                     Affiliate  of  Genesis  Biopharma
                                     granted a Sub-licence  by Genesis
                                     Biopharma  in   accordance   with
                                     Clause 2.4.

"Territory"                          means the world.

"Third Party"                        means any  entity or person  other than the
                                     Parties or an Affiliate of either of them.

"Tobacco Party"                      means any corporation, company, partnership
                                     or  other  organisation  or  person  with a
                                     material   interest  in  or  links  to  the
                                     tobacco industry.

                                       8
<PAGE>
"Viragen Intellectual Property"      means  any Know  How,  Material  or  Patent
                                     Rights directly  related to the development
                                     of  antibodies   directed  against  [****],
                                     whether as an  improvement  to the Licensed
                                     Intellectual    Property   or    otherwise,
                                     discovered,    invented,    developed,   or
                                     manufactured   as  a  result  of   research
                                     undertaken   by   Viragen   itself  or  its
                                     Affiliates  or  Sub-licensees  or  research
                                     funded by Viragen but undertaken by a Third
                                     Party and  whether  undertaken  pursuant to
                                     the 2005  Licence or pursuant to the Letter
                                     Agreement, assigned to Genesis Biopharma by
                                     Hamilton  under  the  terms  of  the  Asset
                                     Purchase Agreement.

1.2 In this Agreement:

     1.2.1    unless  the  context  otherwise  requires,  all  references  to  a
              particular  Clause or schedule shall be a reference to that Clause
              or schedule in or to this Agreement as it may be amended from time
              to time pursuant to this Agreement;

     1.2.2    the  headings  are  inserted  for  convenience  only and  shall be
              ignored in construing this Agreement;

     1.2.3    unless  the  contrary  intention  appears,   words  importing  the
              masculine  gender  shall  include the  feminine and vice versa and
              words in the singular include the plural and vice versa;

     1.2.4    unless the contrary  intention  appears,  words denoting "persons"
              shall include any individual,  partnership,  company, corporation,
              joint venture, trust association, organisation or other entity, in
              each case whether or not having separate legal personality;

     1.2.5    the  words  "include",   "included"  and  "including"  are  to  be
              construed  without  limitation to the  generality of the preceding
              words; and

     1.2.6    reference to any statute or regulation  includes any  modification
              or re-enactment of that statute or regulation.

2.   GRANT OF LICENCE

2.1  In  consideration  for the payments to be made by Genesis  Biopharma to CRT
     pursuant to Clause 4, CRT hereby  grants to Genesis  Biopharma an exclusive
     worldwide  right  and  licence  under  all of its  rights  in the  Licensed
     Intellectual  Property to research,  develop,  use, keep,  make, have made,
     market, distribute,  sell, offer to sell, advertise or otherwise dispose of
     Products in the Field. Genesis Biopharma hereby acknowledges that as of the
     Commencement  Date it is already in possession of the Licensed Know How and

                                       9
<PAGE>
     Licensed  Materials  and CRT is  under no  obligation  to  provide  further
     quantities of such Licensed Know How and Licensed Materials.

2.2  Subject to Clause 2.3, the licence granted in Clause 2.1 shall, in relation
     to a particular country in the Territory, terminate on:

     2.2.1    the  expiry  of the  relevant  Licensed  Patent  in  the  relevant
              country; or

     2.2.2    ten years  after the date that the first  therapeutic  Product was
              placed on the market in such country,

     whichever is the later.

2.3  It is acknowledged and agreed that:

     2.3.1    this Agreement  shall be subject to the academic  research  rights
              granted  to  the  University   under  the  Licensed   Intellectual
              Property; and

     2.3.2    [************************************************************]

2.4  Genesis Biopharma shall have the right to grant  Sub-licences of any or all
     of the rights  granted to it  pursuant to Clause 2.1 to a Third Party or an
     Affiliate if, in respect of each  Sub-licence,  Genesis  Biopharma  ensures
     that CRT's  rights under this  Agreement  are  maintained  and that Genesis
     Biopharma meets the material terms and conditions of the Agreement.  In the
     case of the grant of a Sub-licence to a Third Party only, Genesis Biopharma
     shall  obtain the prior  written  consent of CRT,  such  consent  not to be
     unreasonably withheld or delayed, provided,  however, that CRT's failure to
     provide  written "good cause" denial of consent within thirty (30) Business
     Days after Genesis Biopharma  requests consent to grant a Sub-licence shall
     be deemed to be consent. Notwithstanding anything to the contrary set forth
     herein, (i) Genesis Biopharma shall have the right to grant Sub-licences of
     any or all of the  rights  granted  to it  pursuant  to  Clause  2.1 to any
     Affiliate  of Genesis  Biopharma  without  obtaining  CRT's  prior  written
     consent  and (ii)  Genesis  Biopharma  shall also have the  right,  without
     obtaining  CRT's  prior  written  consent,  to  enter  into a  sub-contract
     manufacturing,  co-marketing or  distribution  agreement with a Third Party
     under  which  Genesis  Biopharma  appoints  a Third  Party as its  agent to
     manufacture,  promote or sell Products. Within thirty (30) Business Days of
     the grant of any  Sub-licence  to a Third Party,  Genesis  Biopharma  shall
     provide CRT with a true copy of the Sub-licence signed by Genesis Biopharma
     and such Third Party, at Genesis  Biopharma's own expense.  Any Sub-licence
     that is  granted  in  breach  of this  Clause  2.4  shall be void.  Without
     prejudice to Genesis Biopharma's  obligation to seek CRT's consent to grant
     Sub-licences  to Third  Parties as set forth  under this  Clause  2.4,  any
     Sub-licence granted by Genesis Biopharma to a Third Party shall be presumed
     to meet the requirements of this Clause 2.4 if it shall:

     2.4.1    be granted on an arm's  length  basis  reflecting  the arms length
              fair market value for 100% cash consideration;

                                       10
<PAGE>
     2.4.2    provide that the  Sub-licence  shall  terminate  automatically  on
              termination for whatever reason of this Agreement;

     2.4.3    provide  that the Third Party with whom the  Sub-licence  has been
              entered into shall undertake to allow Genesis  Biopharma access to
              such Third Party's books and records  relating to the  calculation
              of Net Sales of  Products,  and Genesis  Biopharma  undertakes  to
              include in its books and records or make  available to CRT all Net
              Sales  information  and records it receives  from such Third Party
              relating to Products;

     2.4.4    provide that, in the event of termination of this  Agreement,  the
              Third  Party  Sub-licensee  shall have the right,  for a period of
              ninety (90) Business Days  following the date of  termination,  to
              sell off stocks of Product held by it at the date of  termination;
              and

     2.4.5    prohibit the  assignment  of the  Sub-licence  to any Third Party;
              provided,  however,  that Genesis  Biopharma shall be permitted to
              permit such Third Party  Sub-licensee  to  sub-license  the rights
              granted to it under the  Sub-licence,  provided  that (1)  Genesis
              Biopharma  shall  ensure  that the  terms of such  sub-sub-licence
              comply with the terms of this Clause 2.4 MUTATIS MUTANDIS; and (2)
              the terms of the sub-sub-licence prohibit the sub-licensing of the
              rights granted  thereunder and Genesis Biopharma shall, at its own
              cost,  provide  a copy of each  sub-sub-licence  to CRT as soon as
              possible after completion.

2.5  Any  breach  of  Clauses  2.3 or 2.4  shall be a  material  breach  of this
     Agreement.

2.6  [************************************************************************].

3.   DEVELOPMENT AND MARKETING PLAN

3.1  Genesis Biopharma shall:

     3.1.1    subject to Clause 3.3, use commercially  reasonable  endeavours to
              undertake the Development Plan at its own cost and expense; and

     3.1.2    provide  [*******] reports for periods ending on [*******]and each
              subsequent  period  of   [*******]months   until  [*******],   and
              thereafter  [*******]reports for periods ending on , outlining its
              and its Affiliates' and any  Sub-licensee's  progress with respect
              to the milestone  deadlines in the Development  Plan and proposing
              any reasonable changes to the Development Plan it requires; and

     3.1.3    spend no less than  [*******] US Dollars  [*******]of  the Initial
              Financing in undertaking  and completing the In Vivo Efficacy Work
              on or before 30 September 2010.

3.2  In the event that Genesis Biopharma  proposes  amendment of the Development
     Plan pursuant to Clause 3.1.2 or otherwise,  the Parties shall discuss such

                                       11
<PAGE>
     amendment in good faith but no amendment to the  Development  Plan shall be
     effective unless made in writing and signed by both Parties.

3.3  In the event that Genesis  Biopharma misses any of the material  milestones
     highlighted in the Development  Plan (as may have been amended  pursuant to
     Clause 3.2) by more than[*******],  such failure shall be a material breach
     of this  Agreement and the Parties shall meet to discuss the matter with an
     aim to come to an agreement on the  reassignment of the milestones,  but on
     doing so, if the Parties cannot reach  agreement,  CRT shall have the right
     to terminate  this  Agreement in  accordance  with the terms of Clause 10.5
     below.  Failure by Genesis Biopharma to deliver to CRT any  [*******]report
     as provided in Clause 3.1.2 shall be a material breach of this Agreement.

3.4  Genesis  Biopharma  shall,  and  shall  procure  that  its  Affiliates  and
     Sub-licensees shall, use their commercially  reasonable  endeavours to: (i)
     obtain all necessary and desirable regulatory and other approvals to market
     and sell Products  (collectively,  "MARKETING  APPROVAL") from any relevant
     Competent  Authority and, upon receipt of Marketing  Approval in a country;
     (ii)  commercialize the Products in each such country to the maximum extent
     practicable;  and (iii) without  limitation of its obligations under Clause
     3.4(i) and (ii) hereof,  adhere to the Marketing  Plan as further set forth
     in Clause 3.5 hereof.

3.5  Commencing with the first full calendar year to occur after the first grant
     of Marketing  Approval for a Product by a Competent  Authority and for each
     calendar  year  thereafter  during  the  term  of  the  Agreement,  Genesis
     Biopharma  shall submit to CRT an annual  Marketing Plan (each a "MARKETING
     PLAN") [*******]after the first day of a calendar year, which shall include
     a  summary  of  the   marketing,   sales  and   distribution   plans  on  a
     country-by-country basis for such calendar year of Genesis Biopharma or its
     Affiliates or Sub-licensees, as applicable. Each Marketing Plan shall be of
     sufficient detail to allow CRT to determine that a highly  professional and
     logical plan has been devised that will support the objective of making the
     Product  available  to as many  patients as possible as early as  possible,
     within the applicable laws and regulations, and thereby generating, growing
     and maintaining  Product sales  throughout the term of this Agreement.  The
     Marketing   Plan  may  be  subject  to  changes  based  upon  local  market
     conditions,  changes in  competition,  changes in other aspects that may be
     expected  to have an impact on local  sales  results  and as a result,  the
     Marketing  Plan shall be subject to change by Genesis  Biopharma upon prior
     written  notice to CRT  (provided,  further,  that the  foregoing  shall be
     without  limitation of the  obligations  of Genesis  Biopharma  pursuant to
     Clause 3.4(i) and (ii) hereof).  All costs relating to the  preparation and
     submission of the Marketing Plans shall be borne by Genesis Biopharma.  All
     Marketing Plans shall be deemed as Confidential Information for purposes of
     this Agreement and CRT shall not provide any Third Party with access to any
     Marketing Plan, or any portion thereof.

4.   CONSIDERATION

4.1  Genesis Biopharma shall pay to CRT:

     4.1.1    [*************************************];

              and

                                       12
<PAGE>
     4.1.2    [*************************************];

              and

     4.1.3    subject to the  provisions of Clauses 4.2, 4.3, 10.6 and 11.4, the
              following payments [********************] of the occurrence of the
              relevant  milestone event  [********************************]  set
              forth in this Clause 4.1.3:

     4.1.3.1  [******************************************]

     4.1.3.2  [******************************************]

     4.1.3.3  [******************************************]

     4.1.3.4  [******************************************]

              and

     4.1.4    subject to the  provisions of Clauses 4.2, 4.3, 10.6 and 11.4, the
              following payments within  [*****************]of the occurrence of
              the relevant milestone event [*********************************]:

              [*******************************************************];

              and

     4.1.5    subject    to    the    provisions    of    Clauses    10.6    and
              11.4[************************* ***************************];

              and

     4.1.6    subject   to  the   provisions   of   Clauses   10.6   and   11.4,
              [************************].

4.2  For the avoidance of doubt [***********************************].

4.3  Notwithstanding  anything to the  contrary  set forth  herein,  (i) Genesis
     Biopharma shall [***********].

4.4  [***********************************************************************].

5.   PAYMENT

5.1  All  payments  due to CRT  under  this  Agreement  shall be made in  pounds
     sterling      in      cleared      funds     to     the      account     of
     [*******************************************************]  (or  such  other
     account details as CRT may from time to time notify to Genesis Biopharma).

                                       13
<PAGE>
5.2  Where sums are  received  by  Genesis  Biopharma  in a currency  other than
     pounds sterling,  conversion of such currencies to pounds sterling shall be
     performed at the closing  mid-spot rate for that currency  published in the
     Financial  Times in London on the last Business Day of the Quarter in which
     the sum is to be paid.

5.3  All costs of transmission or currency  conversion shall be borne by Genesis
     Biopharma.

5.4  All payments by Genesis Biopharma to CRT under this Agreement are expressed
     to be exclusive of value added tax howsoever arising, and Genesis Biopharma
     shall pay to CRT in addition to those  payments or if earlier on receipt of
     a tax  invoice or invoices  from CRT,  all Value Added Tax for which CRT is
     liable to account in  relation  to any supply made or deemed to be made for
     Value Added Tax purposes pursuant to this Agreement.

5.5  All payments to CRT shall be made free and clear of, and without  deduction
     or deferment in respect of, any claims, set-off and taxes imposed or levied
     by any Competent  Authority  including any withholding  taxes. In the event
     that Genesis  Biopharma is obliged to deduct any withholding or other taxes
     it shall  pay to CRT an  amount as shall  result  in the net  amount  being
     received by CRT being equal to the amount which would have been received by
     CRT had no deduction or withholding been made; provided always that, if CRT
     is able to recover or set-off any such deduction or  withholding,  it shall
     refund such amount to Genesis  Biopharma  as shall result in the net amount
     being  retained  by CRT being  equal to the  amount  which  would have been
     received by CRT had no deduction or withholding been made.

5.6  The provisions of Clause 5.5 above  requiring  Genesis  Biopharma to pay to
     CRT a sum such that the net amount  received  by CRT is equal to the amount
     that would have been received by CRT had no deduction or  withholding  been
     made  shall  not  apply  if,  and only to the  extent  that,  the  relevant
     deduction  results from Genesis  Biopharma  being under a legal  obligation
     under the UK tax rules requiring  Genesis Biopharma to deduct income tax at
     source from royalties  payable by Genesis  Biopharma to CRT in respect of a
     UK granted patent.

5.7  Where   CRT   does   not   receive   payment   of  any   sums   due  to  it
     [*******************] interest shall accrue on the sum due and owing to CRT
     at the rate  equivalent  to an annual  rate of three per cent (3%) over the
     then current base rate of the Bank of England,  for the UK, calculated on a
     daily basis, without prejudice to CRT's right to receive payment on the Due
     Date.

6.   BOOKS AND RECORDS

6.1  Pursuant to Clause 4.4, Genesis  Biopharma shall prepare  [*******]Reports.
     The  [*******]Reports  shall  include Net Sales by country,  including  the
     company  making the sales and the  amount of  Products  sold.  If CRT gives
     notice to Genesis  Biopharma  within  [*******]of  the  receipt of any such
     [*******]Report  that it does not  accept  the same,  that  [*******]Report
     shall be  certified  by an  independent  accountant  appointed by agreement
     between  Genesis  Biopharma  and CRT or, in  default  of  agreement  within
     [*******]Days,  appointed  by the  President  for  the  time  being  of the
     Institute of Chartered Accountants of England and Wales in London.  Genesis
     Biopharma shall (subject to the independent accountant agreeing to maintain
     the  confidentiality  of the books and records save insofar as is necessary
     for the proper  reporting to Genesis  Biopharma and CRT) make  available to

                                       14
<PAGE>
     the independent  accountant all books and records  required for the purpose
     of that  certification  and the statements so certified  shall be final and
     binding  between the Parties.  The cost of the  certification  shall be the
     responsibility  of  Genesis  Biopharma  if the  statement  is shown to have
     underestimated  the monies  payable to CRT  [********************]  and the
     responsibility of CRT otherwise.  Any outstanding payments due to CRT which
     are identified as a result of carrying out the investigation  shall be paid
     to [********************]. There shall be no more than one certification by
     an independent accountant in relation to any one calendar year.

6.2  Genesis  Biopharma  shall  keep  true and  accurate  records  and  books of
     account,  and shall require in its contracts  with  Sub-licensees  that its
     Sub-licensees  shall keep true and  accurate  records and books of account,
     containing all data necessary for the calculation of the amounts payable by
     Genesis Biopharma to CRT pursuant to this Agreement, including such amounts
     payable  pursuant to Clause 2.4.3.  Such records and books of account shall
     be kept for six (6) years  following  the end of the calendar year to which
     they relate and  Genesis  Biopharma's  records and books of account  shall,
     upon  reasonable  notice  having been given by CRT,  be open at  reasonable
     times on Business Days for  inspection  under the terms of  confidentiality
     contained  in  this  Agreement,  by  an  independent  firm  of  accountants
     appointed  by  agreement  between the Parties or,  failing  such  agreement
     within ten (10)  Business  Days,  appointed by the  President  for the time
     being of the  Institute  of Chartered  Accountants  of England and Wales in
     London.  The cost of any  such  examination  shall  be  borne by CRT,  such
     examination  to take  place and be  completed  not later than six (6) years
     following the  expiration of the period to which it relates and there shall
     be no more than one examination per year.

7.   MANAGEMENT OF PATENT RIGHTS; OWNERSHIP OF INTELLECTUAL PROPERTY

7.1  Subject to Clauses 7.4, 7.5 and 7.6 hereof,  Genesis  Biopharma shall, from
     the Commencement Date,  undertake or procure the filing,  prosecution,  and
     maintenance of the Licensed Intellectual  Property,  including the Licensed
     Patents,  in  the  name  of CRT  and be  responsible  for  any  enforcement
     proceedings  relating to them  (including  any  interference  or opposition
     proceedings);  provided,  further,  that the  Parties  agree  that  Genesis
     Biopharma's  obligations  hereunder  shall  extend  only  within  the Field
     (unless such filing, prosecution or maintenance is not separable by Field).
     Genesis   Biopharma   or  CRT  shall   provide   copies  of  all   relevant
     correspondence  to CRT or  Genesis  Biopharma,  as the case may be,  within
     [*******]of receipt, and the Parties shall consult in all material respects
     with each other in relation to such filing,  prosecution,  and maintenance.
     Genesis  Biopharma  shall  also be  responsible  for  payment  of all  fees
     incurred  by or on  instructions  of  Percipio  but  which  are not paid by
     Percipio. Genesis Biopharma shall not appoint or change any outside firm of
     Patent Attorneys appointed to represent it in the efforts described in this
     Clause 7.1 without CRT's prior written consent (which consent CRT shall not
     unreasonably withhold).

7.2  Each Party shall give the other immediate notice of any actual or suspected
     infringement of the Licensed  Patents or any actual or suspected  misuse or
     misapplication of the Licensed Know How and/or the Licensed  Materials by a
     Third Party which comes to that Party's  attention  during the term of this
     Agreement.

                                       15
<PAGE>
7.3  If either Party receives any notice,  claim, or proceedings  from any Third
     Party alleging  infringement of that Third Party's intellectual property by
     reason of either  Party's  activities in relation to this  Agreement or the
     use and  exploitation of the Licensed  Intellectual  Property in the Field,
     the        Party         receiving         that        notice         shall
     [*************************************]  notify  the  other  Party  of  the
     notice, claim or proceeding.

7.4  Genesis  Biopharma may (subject to Clause 7.5), at its own cost, defend and
     enforce or may procure the defence or  enforcement  of the rights under the
     Licensed  Intellectual  Property in the Field,  including any  interference
     proceedings.  CRT  shall,  at  Genesis  Biopharma's  cost,  render all such
     reasonable   assistance   as   Genesis   Biopharma   reasonably   requests.
     [*****************************]

7.5  If Genesis  Biopharma elects not to defend or enforce the relevant Licensed
     Intellectual  Property  in the  Field  pursuant  to  Clause  7.4 and if CRT
     desires the  enforcement  or defence of such rights it shall notify Genesis
     Biopharma and Genesis Biopharma shall, at CRT's request [******],  grant to
     CRT any and all rights  that would be  necessary  solely for the purpose of
     allowing CRT to undertake such enforcement or defence. If Genesis Biopharma
     is unable to grant such rights then it shall,  at CRT's  request,  grant to
     CRT the right to conduct  such an action in its name.  CRT shall defend and
     enforce or shall  procure the defence or  enforcement  of the rights  under
     Licensed  Intellectual  Property  in the Field  pursuant to this Clause 7.5
     [**********].   Genesis  Biopharma  shall  provide,  [********],  all  such
     reasonable   assistance  as  CRT  may   reasonably   request  in  any  such
     proceedings. [*************************************************].

7.6  In the event that the Licensed Intellectual Property is licensed to a Third
     Party outside the Field for  commercial  purposes the costs and expenses in
     relation  to the  prosecution,  maintenance  and  defence  of the  Licensed
     Intellectual Property referred to in this Clause 7 shall no longer be borne
     by Genesis Biopharma alone and CRT undertakes to ensure that such costs and
     expenses  shall be  apportioned  as between  each  licensee of the Licensed
     Intellectual  Property in shares  reflecting  the  commercial  value of the
     Licensed Intellectual Property in the respective fields.  However,  nothing
     herein,  including  any  licence  to a Third  Party by CRT,  shall  prevent
     Genesis  Biopharma  from  exercising  its rights  under Clause 7.4, and CRT
     agrees to take all steps  necessary  with said  Third  Parties  to grant to
     Genesis  Biopharma any and all rights necessary to allow Genesis  Biopharma
     to undertake such  enforcement or defence.  CRT further agrees that it will
     not allow any Third  Party to enforce or defend the  Licensed  Intellectual
     Property,  either  within or outside the Field,  without the prior  express
     written permission of Genesis Biopharma.

7.7  CRT shall,  [*************],  provide such reasonable assistance and advice
     to Genesis  Biopharma  as Genesis  Biopharma  may  request  (including  the
     provision  of copies of any  necessary  documents)  which is  necessary  or
     desirable  for Genesis  Biopharma  to apply for an extension to the term of
     protection of the Licensed  Patents in the Field including any SPC or other
     like form of protection anywhere in the Territory.

7.8  As between the Parties, their Affiliates and Sub-licensees: (i) all rights,
     title and interest in the Genesis Biopharma  Intellectual Property shall be
     exclusively  owned by  Genesis  Biopharma  and (ii) all  rights,  title and

                                       16
<PAGE>
     interest  in any  clinical  data  or  regulatory  filings  relating  to the
     Products shall be exclusively owned by Genesis Biopharma.

8.   WARRANTIES AND LIABILITY

8.1  [**********************************]

     8.1.1    [****************************************]

     8.1.2    [****************************************]

8.2  [**********************************].

8.3  [**********************************].

8.4  [**********************************].

8.5  [**********************************].

8.6  [**********************************].

8.7  [**********************************].

8.8  [**********************************].

8.9  [**********************************].

9.   CONFIDENTIALITY

9.1  Each Party undertakes to keep secret and confidential and agrees not at any
     time for any reason  whatsoever  disclose or permit to be  disclosed to any
     Third Party or otherwise make use of or permit use to be made of (except as
     expressly permitted by this Agreement), any Confidential Information of the
     disclosing  Party  and/or  Know  How of the  disclosing  Party  and/or  the
     Licensed  Intellectual  Property  which  come  into the  recipient  Party's
     possession during the term of this Agreement.

9.2  The Parties shall ensure that only those of, and their  Affiliates'  and/or
     Sub-licensees',  their  directors,  officers and employees who need to have
     access to  Confidential  Information  and/or  Know How and/or the  Licensed
     Intellectual  Property for the proper performance of this Agreement and any
     Sub-licence  do have access and that those who are directly  concerned with
     the  performance of this Agreement and any  Sub-licence and who have access
     to the  Confidential  Information  and/or Know How of the disclosing  Party
     and/or the  Licensed  Intellectual  Property are informed of its secret and
     confidential  nature and the recipient Party undertakes to ensure that such
     of its, and its Affiliates' and its Sub-licensees', directors, officers and
     employees to whom the Confidential  Information  and/or Know How and/or the
     Licensed  Intellectual  Property is  disclosed  shall  have,  prior to such
     disclosure, executed a confidentiality undertaking on terms no less onerous
     than  those  contained  in  this  Agreement  or  that  such  disclosure  is

                                       17
<PAGE>
     adequately  governed  by the terms of the  contract of  employment  of such
     director, officer or employee.

9.3  The obligations of confidence referred to in this Clause 9 shall not extend
     to any  Confidential  Information or Know How or the Licensed  Intellectual
     Property which:

     9.3.1    is at the time of  disclosure,  or thereafter  becomes,  generally
              available  to the public  otherwise  than by reason of a breach by
              the recipient Party of the provisions of this Agreement; or

     9.3.2    is known to the recipient Party without  obligations of confidence
              prior to its receipt from the disclosing Party, as can be shown by
              written record; or

     9.3.3    is   subsequently   disclosed  to  the  recipient   Party  without
              obligations   of   confidence  by  another  party  owing  no  such
              obligations in respect thereof; or

     9.3.4    is required to be disclosed by any applicable law or any Competent
              Authority to which a Party is from time to time subject; or

     9.3.5    is  independently  developed by a person or persons with no access
              to  the  Confidential   Information   disclosed  by  a  Party,  as
              demonstrated by written records; or

     9.3.6    is  required  to  be  or  is  necessarily  disclosed  through  the
              marketing of a Product embodying Licensed Intellectual Property or
              to any Competent  Authority or by the rules of any stock exchange,
              including for the avoidance of doubt the United States  Securities
              and  Exchange  Commission  pursuant  to relevant  U.S.  securities
              regulations,  and as may be required  under the National Audit Act
              1983 or  otherwise  legally  required  to be  disclosed,  provided
              always that the recipient  Party shall use its best  endeavours to
              limit any such  disclosure  to a minimum and shall,  if reasonably
              possible,  prior to such disclosure,  provide the disclosing Party
              with sufficient  notice,  in order to obtain a protective or other
              order as a court of competent jurisdiction shall award.

9.4  The  obligations  of each Party under  Clauses  9.1-9.3  shall  survive the
     expiration or termination for whatever reason of this Agreement.

10.  TERM AND TERMINATION

10.1 This Agreement shall come into effect on the Commencement  Date and, unless
     sooner terminated as provided  hereunder,  shall continue in full force and
     effect until the termination of all licences  granted to Genesis  Biopharma
     pursuant to Clause 2.1 above. [*********************]

10.2 CRT may, on [*******]written notice, terminate this Agreement if:

                                       18
<PAGE>
     10.2.1   Genesis Biopharma takes any action, serves any notice or commences
              any proceedings seeking to revoke or challenge the validity of the
              Licensed Patent or if it procures or assists a Third Party to take
              any such action; or

     10.2.2   the Financing Event has not occurred prior to expiry of the period
              of [*******]after the Commencement Date; or

     10.2.3   at any time prior to the listing of shares of Genesis Biopharma on
              a public exchange,  in the event of a change of Control of Genesis
              Biopharma  where the new  Controlling  party is a  Tobacco  Party.
              "Control" for the purposes of this  sub-clause  means the power to
              secure that the affairs of Percipio are  conducted  in  accordance
              with the wishes of another  whether  through  ownership  of 50% or
              more of the voting  securities of Genesis Biopharma or by contract
              or otherwise and "Controlling" shall be construed accordingly.

10.3 [************************************************].

10.4 [************************************************].

10.5 Either  CRT on the one hand or  Genesis  Biopharma  on the other  hand (the
     "TERMINATING  PARTY")  shall  have the right to  terminate  this  Agreement
     forthwith upon giving written notice of termination to Genesis Biopharma on
     the one hand or CRT on the other  hand as the case may be (the  "DEFAULTING
     PARTY"),  upon the  occurrence of any of the  following  events at any time
     during this Agreement:

     10.5.1   the Defaulting  Party commits a material  breach of this Agreement
              which in the  case of a  breach  capable  of  remedy  has not been
              remedied  [******************]after  the receipt by the Defaulting
              Party from the Terminating Party of written notice identifying the
              breach and requiring its remedy;

     10.5.2   the Defaulting Party [*******]  [**********************]  suspends
              payment of its debts or otherwise  ceases or threatens to cease to
              carry on its business or becomes bankrupt or insolvent  (including
              without limitation being deemed to be unable to pay its debts);

     10.5.3   a proposal is made or a nominee or  supervisor  is appointed for a
              composition in satisfaction  of the debts of the Defaulting  Party
              or a scheme or arrangement of its affairs, or the Defaulting Party
              enters into any  composition or arrangement for the benefit of its
              creditors,  or  proceedings  are  commenced  in  relation  to  the
              Defaulting Party under any law,  regulation or procedure  relating
              to the  re-construction or re-adjustment of debts (including where
              a  petition  is  filed  or   proceeding   commenced   seeking  any
              reorganisation,  arrangement,  composition or re-adjustment  under
              any applicable bankruptcy, insolvency, moratorium,  reorganisation
              or other  similar  law  affecting  creditor's  rights or where the
              Defaulting Party consents to, or acquiesces in, the filing of such
              a petition); or

                                       19
<PAGE>
     10.5.4   the Defaulting  Party takes any action,  or any legal  proceedings
              are started or other steps are taken by a Third Party, with a view
              to:

               (a)  the winding up or dissolution of the Defaulting Party (other
                    than for the  reconstruction  of a solvent  company  for any
                    purpose,  including  the  inclusion of any part of the share
                    capital of the Defaulting Party on a recognised public stock
                    exchange); or

               (b)  the   appointment  of  a  liquidator,   trustee,   receiver,
                    administrative  receiver,   receiver  and  manager,  interim
                    receiver  custodian,  sequestrator or similar officer of the
                    Defaulting   Party  against  the   Defaulting   Party  or  a
                    substantial part of the assets of the Defaulting Party; or

               (c)  the  undertaking  of  anything   analogous  to  any  of  the
                    foregoing under the laws of any country.

10.6 [****************************************************].

11.  CONSEQUENCES OF TERMINATION

11.1 Subject to Clauses 10.6 and 11.4 upon termination of this Agreement:

     11.1.1   the licence rights granted by CRT to Genesis Biopharma pursuant to
              Clause 2 shall terminate and any  Sub-licences  granted by Genesis
              Biopharma pursuant to Clause 2.4 shall terminate;

     11.1.2   Genesis  Biopharma shall pay to CRT within  [********************]
              all sums due to CRT hereunder which have accrued prior to the date
              of termination;

     11.1.3   each recipient of Confidential  Information  shall promptly return
              to each  disclosing  Party,  or, at the  option of the  disclosing
              Party, destroy, all Confidential  Information held in hard copy or
              electronic  form which has been  provided to the  recipient  Party
              save that each  recipient  Party shall be  permitted to retain one
              copy of any document containing such Confidential  Information for
              the purposes of ensuring its continuing  compliance  with Clause 9
              and for no other purpose; and

     11.1.4   upon   written   request   by  CRT,   Genesis   Biopharma   shall,
              [*************************]  of receipt of said notice,  return to
              CRT, or, at CRT's option,  destroy all Licensed  Materials held by
              Genesis Biopharma.  Nothing herein shall require Genesis Biopharma
              to return publicly  available material or other materials that are
              the subject of Clause 9.3, above.

11.2 Subject to the provisions of Clause 10.6:

     11.2.1   Genesis   Biopharma  shall  provide  to  CRT  within   [*******]of
              termination of this Agreement one copy of each document containing
              information,  together with any information  held in an electronic
              form, in each case in reasonably  sufficient  detail to enable CRT

                                       20
<PAGE>
              itself or through a Third Party to further develop  Products;  (a)
              relating  directly to the Licensed  Intellectual  Property  and/or
              developed or acquired by Genesis Biopharma whilst  undertaking the
              Development  Plan; and (b) comprised  within Viragen  Intellectual
              Property,   Percipio  Intellectual  Property,   Genesis  Biopharma
              Intellectual   Property  and/or  clinical  data  relating  to  the
              Licensed  Intellectual  Property to which  Genesis  Biopharma  has
              rights.

     11.2.2   Genesis  Biopharma  shall  provide to CRT within  [*******]of  the
              Commencement  Date and on each  anniversary  thereof,  one copy of
              each such document,  together with any such information held in an
              electronic  form, as referred to in Clause  11.2.1,  which pending
              accrual of CRT's rights under  Clauses 11.1 or 11.3 CRT shall hold
              to the order of Genesis Biopharma.

11.3 In the event of termination:

     11.3.1   By  Genesis  Biopharma  pursuant  to  Clauses  10.3  or  10.4 in a
              particular  country,  then Genesis Biopharma agrees to provide CRT
              with an  exclusive,  sub-licensable  licence  to use the  Percipio
              Intellectual  Property,  the Viragen  Intellectual  Property,  the
              Genesis  Biopharma  Intellectual  Property and all  clinical  data
              relating  to the  Licensed  Intellectual  Property to which it has
              rights, to research,  develop, use, keep, make, have made, market,
              distribute, sell, offer to sell, advertise or otherwise dispose of
              Products in the Field in that  country or  countries  on a Revenue
              Share basis;

     11.3.2   By  Genesis  Biopharma  pursuant  to  Clauses  10.3 or 10.4 in the
              entire  Territory,  or by CRT pursuant to Clauses  10.2.2 or 10.5,
              then  Genesis  Biopharma  agrees  to  assign  to CRT the  Percipio
              Intellectual  Property,  the Viragen Intellectual Property and the
              Genesis  Biopharma  Intellectual  Property and all  clinical  data
              relating  to the  Licensed  Intellectual  Property to which it has
              rights, on a Revenue Share basis.

11.4 In the event of the expiry of this  Agreement  or the  termination  of this
     Agreement by Genesis Biopharma  pursuant to Clause 10.5, CRT shall grant to
     Genesis  Biopharma a non-exclusive,  perpetual,  fully paid up royalty-free
     licence to the Licensed  Intellectual  Property to research,  develop, use,
     keep, make, have made, market,  distribute,  sell, offer to sell, advertise
     or otherwise dispose of the Products in the Territory.  In the event of (i)
     a termination of a licence in a country (except pursuant to Clauses 10.3 or
     10.4) or (ii) the  occurrence of an event as set forth in Clause 10.6,  CRT
     shall grant to Genesis Biopharma a non-exclusive,  perpetual, fully paid up
     royalty-free  licence to the  Licensed  Intellectual  Property to research,
     develop,  use, keep, make, have made,  market,  distribute,  sell, offer to
     sell,  advertise  or  otherwise  dispose of the  Products in such  country.
     Notwithstanding  anything to the contrary set forth in this Clause 11.4, if
     CRT shall  terminate  the Agreement  pursuant to Clauses 10.2 or 10.5,  the
     licence shall terminate.

11.5 If Genesis  Biopharma  serves  notice to  terminate  this  Agreement in the
     Territory or in  particular  countries  pursuant to Clauses 10.3 or 10.4 it
     shall,  without  prejudice to its  obligation to pay  royalties  during the
     notice period,  pay to CRT all of any milestone  payment which has not been

                                       21
<PAGE>
     paid and in respect of which the milestone event has been achieved prior to
     the  date  of  notification  by  Genesis  Biopharma  of  its  intention  to
     terminate.

11.6 Notwithstanding  anything to the contrary herein, the termination or expiry
     of this  Agreement for whatever  reason shall not affect the accrued rights
     of the Parties  arising in any way out of this  Agreement as at the date of
     termination or expiry and in particular but without limitation the right to
     recover damages and interest,  and the provisions of Clauses 2.3, 2.6, 6.2,
     7.7 (but only to the extent  that a licence  has been  granted  pursuant to
     Clause 11.4 hereof), 7.8, 8.1-8.9,  9.1-9.4,  10.6,  11.1-11.8,  14.1-14.2,
     17.1-17.3, 18.1, 18.2, 19.1, 20.1, 20.2, 21.1 and 22.1-22.3 shall remain in
     full force and effect.

11.7 Notwithstanding  the provisions of Clause 11.1.1,  termination or expiry of
     this Agreement for whatever reason shall be without prejudice to the rights
     of Genesis  Biopharma and/or its permitted  Sub-licensees to fulfill orders
     received  prior to the  termination  or expiry  subject  to the  payment of
     royalties on any Net Sales accruing in respect thereof at the rates set out
     in this Agreement.

11.8 [***************************************************].

12.  WAIVER

12.1 Neither  Party shall be deemed to have waived any of its rights or remedies
     conferred by this Agreement unless the waiver is made in writing and signed
     by a duly authorised  representative of that Party. In particular, no delay
     or failure of either Party in  exercising or enforcing any of its rights or
     remedies  conferred by this  Agreement  shall  operate as a waiver of those
     rights  or  remedies  or  so as to  preclude  or  impair  the  exercise  or
     enforcement  of those rights or remedies nor shall any partial  exercise or
     enforcement  of any right or remedy by either Party  preclude or impair any
     other exercise or enforcement of that right or remedy by that Party.

13.  ENTIRE AGREEMENT/VARIATIONS

13.1 Save for the Licence  Termination and Waiver Agreement and the Confirmatory
     Waiver  Agreement of even date  herewith,  this Agreement  constitutes  the
     entire agreement and  understanding  between the Parties and supersedes all
     prior  oral or written  understandings,  arrangements,  representations  or
     agreements between them relating to the subject matter of this Agreement.

13.2 No director,  employee or agent of either Party is  authorised  to make any
     representation  or  warranty  to the  other  Party  not  contained  in this
     Agreement,  and each Party  acknowledges that it has not relied on any such
     oral or written  representations  or warranties.  Nothing in this Clause 13
     shall operate to limit or exclude any liability for fraud.

13.3 No variation,  amendments,  modification  or  supplement to this  Agreement
     shall be valid unless made in writing in the English language and signed by
     a duly authorised representative of both Parties.

                                       22
<PAGE>
13.4 In the event of any conflict or discrepancy  between this Agreement and any
     other agreement,  schedule or amendment,  the terms of this Agreement shall
     control unless superseded by subsequent written agreement.

14.  NOTICES

14.1 Any notice to be given  pursuant to this  Agreement  shall be in writing in
     the English  language  and shall be  delivered  by hand,  sent by overnight
     registered or recorded delivery airmail post or sent by facsimile confirmed
     by registered or recorded  delivery post to the address or facsimile number
     of the recipient set out below or such other address or facsimile number as
     a Party  may from time to time  designate  by  written  notice to the other
     Parties.

     ADDRESS OF GENESIS BIOPHARMA

     Genesis Biopharma, Inc.
     Suite 200
     8275 Eastern Ave.
     Las Vegas, Nevada
     USA

     For the attention of Robert Brooke
     Chief Executive Officer

     Fax No. +1 (310) 696-0334

     ADDRESS OF CRT

     Sardinia House
     Sardinia Street
     London
     WC2A 3NL

     Fax No. +44 (0) 20 7269 3641

     For the attention of the Chief Executive.

14.2 Any notice  given  pursuant  to this Clause 14 shall be deemed to have been
     received:

     14.2.1   in the case of delivery by hand, when delivered; or

     14.2.2   in the  case  of  sending  by  overnight  registered  or  recorded
              delivery airmail post on the second Business Day following the day
              of posting; or

     14.2.3   in the case of  facsimile,  on  acknowledgement  by the  recipient
              facsimile receiving equipment if the acknowledgement occurs before
              1700 hours local time of the  recipient  on a Business  Day and in
              any other case on the following Business Day.

                                       23
<PAGE>
15.  ASSIGNMENT

15.1 Neither Party shall  without the prior written  consent of the other Party,
     assign the benefit and/or burden of this Agreement nor  sub-contract any of
     its obligations hereunder unless otherwise permitted by the terms hereof.

16.  FORCE MAJEURE

16.1 If a Party (the  "NON-PERFORMING  PARTY") is unable to carry out any of its
     obligations  under this Agreement due to Force Majeure this Agreement shall
     remain in effect but the Non-Performing  Party's relevant obligations under
     this  Agreement  and the  relevant  obligations  of the  other  Party  (the
     "INNOCENT  PARTY")  under this  Agreement  shall be suspended  for a period
     equal  to  the  duration  of  the   circumstance   of  Force  Majeure  (the
     "SUSPENSION") provided that:

     16.1.1   the  Suspension  is of no greater  scope than is  required  by the
              Force Majeure;

     16.1.2   the  Non-Performing  Party gives the Innocent  Party prompt notice
              describing the circumstance of Force Majeure, including the nature
              of the  occurrence  and its expected  duration,  and  continues to
              furnish regular reports during the period of Force Majeure;

     16.1.3   the Non-Performing Party uses all reasonable efforts to remedy its
              inability   to  perform  and  to  mitigate   the  effects  of  the
              circumstance of Force Majeure; and

     16.1.4   as soon as  practicable  after the event which  constitutes  Force
              Majeure the  Parties  shall  discuss  how best to  continue  their
              operations as far as possible in accordance with this Agreement.

16.2 If the Suspension continues for a period of [*******]the Innocent Party may
     give [*******]written  notice thereafter to terminate this Agreement to the
     Non-Performing  Party and  termination  shall occur if the Force Majeure is
     continuing at the end of that [*******]notice period.

17.  DISPUTE RESOLUTION

17.1 Any  question,  difference  or  dispute  which  may  arise  concerning  the
     construction  meaning or effect of this  Agreement or concerning the rights
     and liabilities of the Parties hereunder or any other matter arising out of
     or in connection  with this Agreement  shall first be submitted to the then
     acting Chief Executive Officer of Genesis Biopharma and the Chief Executive
     of CRT who may call on others to advise them as they see fit.

17.2 If the  discussions  under Clause 17.1 should fail to resolve the question,
     difference  or dispute  within[*******],  the Parties  agree to try in good
     faith to settle the matter by mediation, but not arbitration,  administered
     by the American  Arbitration  Association  under its  Commercial  Mediation
     Rules. Any mediation under this Clause 17.2 shall take place in London.  If
     mediation  should  fail to  resolve  the  question,  difference  or dispute

                                       24
<PAGE>
     within[*******], the Parties agree that either Party may seek resolution of
     such question, difference or dispute in court pursuant to Clause 22.1.

17.3 Notwithstanding the foregoing, and notwithstanding Clause 22, any Party may
     seek  immediate  injunctive  or other  interim  relief  from  any  court of
     competent  jurisdiction  with  respect  to any  matter  for which  monetary
     damages would not adequately protect such Party's interests or otherwise to
     enforce and protect intellectual  property rights owned or licensed to such
     Party.

18.  SEVERANCE OF TERMS

18.1 If the whole or any part of this  Agreement  is or becomes  or is  declared
     illegal,  invalid  or  unenforceable  in any  jurisdiction  for any  reason
     (including  both by reason of the provisions of any legislation and also by
     reason of any court or Competent  Authority  which either has  jurisdiction
     over this Agreement or has jurisdiction over any of the Parties):

     18.1.1   in the case of the illegality,  invalidity or  unenforceability of
              the whole of this Agreement it shall terminate only in relation to
              the jurisdiction in question; or

     18.1.2   in the case of the illegality,  invalidity or  unenforceability of
              part of this  Agreement  that  part  shall be  severed  from  this
              Agreement in the  jurisdiction  in question  and that  illegality,
              invalidity  or  unenforceability  shall not in any way  whatsoever
              prejudice or affect the remaining  parts of this  Agreement  which
              shall continue in full force and effect.

18.2 If in the reasonable  opinion of any Party any severance  under this Clause
     18 materially  affects the commercial basis of this Agreement,  the Parties
     shall discuss, in good faith, ways to eliminate the material effect.

19.  THIS AGREEMENT NOT TO CONSTITUTE A PARTNERSHIP

19.1 None of the  provisions of this  Agreement  shall be deemed to constitute a
     partnership  between the Parties and neither of the Parties  shall have any
     authority  to  bind  the  other  in any  way  except  as  provided  in this
     Agreement.

20.  PUBLIC STATEMENTS

20.1 Except as provided in Clause 20.2,  neither Party shall,  without the prior
     written consent of the other Party:

     20.1.1   use  in  advertising,   publicly  or  otherwise,  any  trade-name,
              personal name, trade mark, trade device,  service mark, symbol, or
              any abbreviation,  contraction or simulation thereof, owned by the
              other Party or its Affiliate; or

     20.1.2   represent,  either  directly  or  indirectly,  that any product or
              service  of the  other  Party or its  Affiliate  is a  product  or
              service of the  representing  Party or its Affiliate or that it is

                                       25
<PAGE>
              made in accordance  with or utilises the  information or documents
              of the other Party or its Affiliate.

20.2 The restrictions in Clause 20.1 shall not apply to the following:

     20.2.1   a press  release,  in a form agreed to in writing by both Parties,
              publicly announcing this Agreement; or

     20.2.2   use as required by any applicable law or governmental  regulation,
              including,  for  the  avoidance  of  doubt,  compliance  with  all
              applicable United States Food and Drug  Administration  and United
              States  federal and state  securities  laws,  including the United
              States Securities and Exchange Commission Rules and requirements.

21.  COSTS

21.1 Each Party shall bear its own legal  costs,  legal fees and other  expenses
     incurred in the preparation and execution of this Agreement.

22.  GOVERNING LAW, JURISDICTION AND PRESUMPTIONS

22.1 All  matters  relating to this  Agreement  shall be governed by the laws of
     England and the Parties  submit to the  non-exclusive  jurisdiction  of the
     English courts.

22.2 This Agreement  shall be deemed to be jointly  created and drafted,  and no
     presumption  shall arise, and no provision shall be construed,  against the
     drafter  of a  particular  section or  provision,  when  interpreting  this
     Agreement.

22.3 No term of this Agreement shall be enforceable  under the Contracts (Rights
     of Third  Parties)  Act 1999 by a person who is not a Party,  but this does
     not  affect  any  right or  remedy  of a third  party  which  exists  or is
     available apart from under that Act.

                                       26
<PAGE>
IN WITNESS whereof this Agreement has been executed by duly authorized  officers
of the Parties on the date first above written.

Signed by:      /s/ P.J. L'Huillier
                --------------------------------------------
Name:           P.J. L'Huillier
                --------------------------------------------
Title:          Director, Business Management
                --------------------------------------------

                For and on behalf of
                CANCER RESEARCH TECHNOLOGY LIMITED

Signed by:      /s/ Robert Brooke
                --------------------------------------------
Name:           Robert Brooke
                --------------------------------------------
Title:          Chief Executive Officer
                --------------------------------------------
                For and on behalf of
                GENESIS BIOPHARMA, INC.

                                       27Exhibit 10.4

                            STOCK PURCHASE AGREEMENT

     THIS STOCK  PURCHASE  AGREEMENT  (this  "Agreement")  is entered into as of
__________, 200__ by and between __________ (the "Seller"), and ____________(the
"Purchaser).

                                  R E C I T A L

     WHEREAS,  the Seller  desires to sell to the  Purchaser,  and the Purchaser
desires to purchase from the Seller,  a total of ______ shares (the "Shares") of
the common  stock,  par value $0.001  ("Common  Stock"),  of Freight  Management
Corporation, a Nevada corporation (the "Company"), registered in the name of the
Seller for an aggregate  purchase price of $____________ (the "Purchase Price"),
upon and subject to the terms and conditions hereinafter set forth.

                                A G R E E M E N T

     Accordingly,  in  consideration  of the premises and the mutual  covenants,
obligations and agreements contained herein, the Purchaser and the Seller hereby
agree as follows:

     1.  Purchase  and Sale of the  Shares.  Upon the terms and  subject  to the
conditions set forth herein, the Seller agrees to sell, and the Purchaser agrees
to purchase the Shares for the Purchase Price.

     2.  Closing.  The  closing  for the  purchase  and sale of the Shares  (the
"Closing")  shall take place on __________  (the  "Closing  Date") at a time and
location to be mutually agreed upon by the parties. Any party may terminate this
Agreement  prior to  Closing,  by  delivering  written  notice  of such  party's
election to terminate this Agreement.  At the Closing,  the Seller shall deliver
to the Purchaser the stock certificates evidencing the Shares, duly endorsed for
transfer  to  the  Purchaser  or  accompanied  by an  assignment  separate  from
certificate, and the Purchaser shall deliver the Purchase Price to the Seller.

     3.  Representation,  Warranties  and  Covenants  of the Seller.  The Seller
hereby represents, warrants and covenants to Purchaser as follows:

          3.1  Authorization;  Enforceability.  The Seller has all  corporate or
individual  right,  power and  authority  to enter  into this  Agreement  and to
consummate the transactions contemplated hereunder. This Agreement has been duly
executed  and  delivered  by the Seller  and  constitutes  the legal,  valid and
binding obligation of the Seller,  enforceable  against the Seller in accordance
with its terms,  subject to laws of general application  relating to bankruptcy,
insolvency  and the  relief  of  debtors  and  rules of law  governing  specific
performance,  injunctive relief or other equitable remedies,  and to limitations
of public policy.

          3.2 Organization,  Good Standing and  Qualification.  The Seller, if a
corporation, is duly organized,  validly existing and in good standing under the
laws of its  jurisdiction  and has full corporate power and authority to conduct
its business.

          3.3 Valid  Transfer.  The Seller is the sole and complete owner of the
Shares  and,  when paid for by the  Purchaser  pursuant to this  Agreement,  the
Purchaser shall receive  complete right,  title and ownership to the Shares free
and clear of any encumbrances or restrictions,  except as provide for under U.S.
federal securities laws.

          3.4 Further  Assurance.  At any time after the  Closing,  Seller shall
execute,  acknowledge  and  deliver  to the  Purchaser  any  further  documents,
assurances or other matters,  and will take any other action consistent with the
terms of this Agreement that may reasonably be requested by the Purchaser and as
are necessary or desirable to carry out the purpose of this Agreement.
<PAGE>
          3.5 No Conflict; Governmental Consents.

               (a) The  execution  and delivery by the Seller of this  Agreement
and the consummation of the transactions  contemplated hereunder will not result
in the violation by the Seller of any law,  statute,  rule,  regulation,  order,
writ,  injunction,  judgment or decree of any court or governmental authority to
or by which the  Seller is bound,  and will not  conflict  with,  or result in a
breach or violation of, any of the terms or provisions  of, or constitute  (with
due notice or lapse of time or both) a default under, any lease, loan agreement,
mortgage,  security agreement, trust indenture, or other agreement or instrument
to which the Seller is a party or by which it is bound.

               (b) No  consent,  approval,  authorization  or other order of any
governmental  authority  or other  third party is required to be obtained by the
Seller in  connection  with the  authorization,  execution  and delivery of this
Agreement or with the sale and transfer of the Shares, except such consents that
have been obtained prior to the Closing.

     4.  Representations  and  Warranties  of Purchaser.  The  Purchaser  hereby
represents and warrants to the Seller as follows:

          4.1 Accredited  Investor.  The Purchaser is an  "accredited  investor"
within  the  meaning  of Rule  501(a)  of  Regulation  D  promulgated  under the
Securities Act.

          4.2  Authorization.  (i) the  purchase of the Shares has been duly and
properly  authorized  and this Agreement has been duly executed and delivered by
the  Purchaser or on its behalf and  constitutes  the valid and legally  binding
obligation  of the  Purchaser,  enforceable  against the Purchaser in accordance
with  its  terms,  subject  to  bankruptcy,   insolvency,  fraudulent  transfer,
reorganization, moratorium and similar laws of general applicability relating to
or affecting  creditors'  rights generally and to general  principles of equity;
(ii)  the  purchase  of the  Shares  does  not  conflict  with  or  violate  the
Purchaser's  organizational  documents,  if any, or any law, regulation or court
order applicable to it; and (iii) the purchase of the Shares does not impose any
penalty  or other  onerous  condition  on  Purchaser  under or  pursuant  to any
applicable law or governmental regulation.

          4.3 Capacity.  The Purchaser has such  knowledge,  sophistication  and
experience in business and  financial  matters so as to be capable of evaluating
the merits and risks of the  prospective  investment  in the Shares,  and has so
evaluated  the  merits  and  risks  of such  investment  and is able to bear the
economic risk of such  investment  and, at the present time, is able to afford a
complete loss of such investment.

          4.4 Reliance on Information.  The Purchaser  acknowledges  that it has
not been provided with a private placement  memorandum or other form of offering
document  regarding  the  Company  or  the  Shares.  Purchaser  understands  the
practical  and  legal  benefits  of  receiving  and  reviewing  such  disclosure
documents and is willing to forego the benefits such  documents  would afford in
order to purchase  the Shares at this time.  To the extent  deemed  necessary or
advisable by the Purchaser,  the Purchaser has retained,  at the sole expense of
Purchaser,  and relied  upon,  appropriate  professional  advice  regarding  the
investment,  tax and legal  merits and  consequences  of this  Agreement  and an
investment in the Shares.

          4.5 No  Solicitation.  The  Purchaser  represents  that no Shares were
offered or sold to  Purchaser  by means of any form of general  solicitation  or
general advertising.

          4.6 Purchase  for Own  Account.  The  Purchaser  understands  that the
Shares have not been registered  under the Securities Act by reason of a claimed
exemption  under  the  provisions  of the  Securities  Act of 1933,  as  amended
("Securities  Act") which  depends,  in part,  upon the  Purchaser's  investment
intention.  In this  connection,  the  Purchaser  hereby  represents  that it is
purchasing Shares for its own account for investment and not with a present view
toward the resale or distribution to others or for resale in connection with any
distribution or public offering  (within the meaning of the Securities Act), nor
with any present intention of distributing or selling the same and the Purchaser
has no present or contemplated agreement, undertaking,  arrangement,  obligation
or commitment  providing for the  disposition  thereof.  The Purchaser shall not
sell or  otherwise  transfer  the  Shares  unless a  subsequent  disposition  is
registered  under the  Securities Act or is exempt from such  registration.  The
Purchaser  consents  to the  placement  of the  legend  set  forth  below,  or a
substantial  equivalent thereof, on any certificate or other document evidencing
the Shares:

                                       2
<PAGE>
        THE SHARES  REPRESENTED  BY THIS  CERTIFICATE  HAVE NOT BEEN
        REGISTERED  UNDER THE UNITED STATES  SECURITIES ACT OF 1933,
        AS AMENDED (THE  "SECURITIES  ACT"), OR ANY APPLICABLE STATE
        SECURITIES  LAWS,  AND MAY NOT BE SOLD,  OFFERED  FOR  SALE,
        PLEDGED OR  HYPOTHECATED  OR  OTHERWISE  TRANSFERRED  IN THE
        ABSENCE OF A  REGISTRATION  STATEMENT IN EFFECT WITH RESPECT
        TO THE SHARES UNDER THE  SECURITIES ACT OR AN EXEMPTION FROM
        THE SECURITIES ACT. ANY SUCH TRANSFER MAY ALSO BE SUBJECT TO
        COMPLIANCE  WITH  APPLICABLE  STATE  SECURITIES LAWS AND THE
        LAWS OF OTHER APPLICABLE JURISDICTIONS.

     5. Miscellaneous.

          5.1 Amendments and Waivers.

               (a)  This   Agreement   sets  forth  the  entire   agreement  and
understanding  between the parties as to the subject  matter  hereof and thereof
and  supersedes  all  prior  and  contemporaneous   discussions,   negotiations,
agreements  and  understandings  (oral or written)  with respect to such subject
matter. This Agreement or any provision hereof may be (i) amended only by mutual
written agreement of the Seller and the Purchaser or (ii) waived only by written
agreement  of the  waiving  party.  No course of  dealing  between  or among the
parties will be deemed effective to modify,  amend or discharge any part of this
Agreement or any rights or  obligations  of any party under or by reason of this
Agreement.

          5.2 Successors and Assigns.  This Agreement  shall be binding upon and
inure to the  benefit of the  Seller  and its  successors  and  assigns  and the
Purchaser and its successors and assigns.

          5.3 Notices. All notices, demands and other communications to be given
or delivered  under or by reason of the provisions of this Agreement shall be in
writing and shall be deemed to duly given and received when delivered personally
or transmitted  by facsimile and properly  addressed to the party to receive the
same at the address  set forth below or at such other  address as such party may
have designated by advance written notice to the other parties.

          If to the Seller:      _________________________
                                 _________________________
                                 _________________________
                                 _________________________
                                 _________________________

          If to the Purchaser:   _________________________
                                 _________________________
                                 _________________________
                                 _________________________
                                 _________________________

          5.4 Governing  Law. This  Agreement  shall be governed by the internal
laws of the State of  California,  without  giving effect to its conflict of law
principles.  All  disputes  between  the  parties  hereto  arising  out of or in
connection  with the  Agreements  or the Shares,  whether  sounding in contract,
tort,  equity or otherwise,  shall be resolved only by state and federal  courts
located  in  Orange  County,  California,  and the  courts  to which  an  appeal
therefrom may be taken.  All parties hereto waive any objections to the location
of the above referenced courts, including but not limited to any objection based
on lack of jurisdiction, improper venue or forum non-conveniens. Notwithstanding
the  foregoing,  any party  obtaining  any order or judgment in any of the above
referenced  courts  may bring an action in a court in  another  jurisdiction  in
order to enforce such order or judgment.

                                       3
<PAGE>
          5.5 Attorneys' Fees. If any action at law or in equity is necessary to
enforce or interpret  the terms of this  Agreement,  the  prevailing  party,  as
specifically determined by the court, shall be entitled to reasonable attorneys'
fees, costs and necessary disbursements in addition to any other relief to which
such party may be entitled.

          5.6  Counterparts.  This  Agreement  may be  executed in any number of
counterparts  and,  notwithstanding  that any of the parties did not execute the
same counterpart, each of such counterparts (or facsimile copies thereof) shall,
for all purposes,  be accepted as an original,  and all such counterparts  shall
constitute  one and the same  instrument  binding on all of the parties  hereto.
Delivery of an executed  counterpart  of a signature  page to this  Agreement by
facsimile shall be as effective as delivery of a manually  executed  counterpart
of a signature page of this Agreement.

          5.7  Headings.  The headings of the Sections  hereof are inserted as a
matter of  convenience  and for  reference  only and in no way define,  limit or
describe the scope of this Agreement or the meaning of any provision hereof.

          5.8 Severability. In the event that any provision of this Agreement or
the  application of any provision  hereof is declared to be illegal,  invalid or
otherwise unenforceable by a court of competent  jurisdiction,  the remainder of
this Agreement  shall not be affected  except to the extent  necessary to delete
such illegal,  invalid or  unenforceable  provision  unless the  provision  held
invalid shall substantially  impair the benefit of the remaining portion of this
Agreement.

                                       4
<PAGE>
      IN WITNESS WHEREOF,  the parties have caused this Stock Purchase Agreement
to be duly executed and delivered as of the date first set forth above.

                                   "SELLER"

                                   --------------------------------------------
                                   [INSERT NAME]

                                   "PURCHASER"

                                   --------------------------------------------
                                   [INSERT NAME]

                                       5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}]]